RIPK1 and brain disorder: A Cu-mediated 18F-labeled positron emission tomography radiotracer, CNY-07, has been shown to target RIPK1 through the blood-brain barrier to characterize the occurrence of necroptosis in the brain and to perform in vivo imaging; in combination with RIPK1 inhibitors such as Nec-1 and DL747, it has been found to be more effective in the treatment of some brain diseases.